$252.8 B

PFE Mkt cap, 15-Oct-2018

$26.4 B

Pfizer Revenue Q2, 2019
Pfizer Gross profit (Q2, 2019)20.9 B
Pfizer Gross profit margin (Q2, 2019), %79.2%
Pfizer Net income (Q2, 2019)7.4 B
Pfizer Cash, 01-Jul-20182.7 B
Pfizer EV279 B

Pfizer Revenue

Pfizer revenue was $52.82 b in FY, 2016 which is a 8.1% year over year increase from the previous period.

Embed Graph

Pfizer Revenue Breakdown

Embed Graph

Pfizer revenue breakdown by business segment: 18.6% from GIP, 17.0% from VOC, 35.6% from Innovative Products and 28.7% from Established Products GEP

Pfizer Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

51.6b49.6b48.9b52.8b

Revenue growth, %

(4%)(2%)8%

Cost of goods sold

9.6b9.6b9.6b12.3b

Gross profit

42.0b40.0b39.2b40.5b

Gross profit Margin, %

81%81%80%77%

Sales and marketing expense

14.4b14.1b14.8b14.8b

R&D expense

6.7b8.4b7.7b7.9b

Operating expense total

21.0b22.5b22.5b22.7b

EBIT

11.4b9.1b7.0b7.2b

EBIT margin, %

22%18%14%14%

Pre tax profit

15.7b12.2b9.0b8.4b

Income tax expense

4.3b3.1b2.0b1.1b

Net Income

22.1b9.2b7.0b7.2b

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q2, 2017Q1, 2019Q2, 2019

Revenue

12.6b11.4b12.8b12.4b10.9b11.9b12.1b12.9b12.9b26.4b

Cost of goods sold

2.3b2.0b2.5b2.4b1.8b2.6b5.5b

Gross profit

10.4b9.3b10.3b10.0b9.0b10.3b20.9b

Gross profit Margin, %

82%82%81%81%83%80%79%

R&D expense

1.6b1.6b1.8b1.8b1.9b1.7b3.5b

General and administrative expense

3.4b3.0b3.5b3.6b3.1b3.4b7.0b

Operating expense total

5.0b4.7b5.3b5.4b5.0b5.2b10.5b

Depreciation and amortization

1.2b2.4b

Pre tax profit

3.6b2.8b4.0b3.6b3.1b2.4b4.1b8.7b

Income tax expense

582.0m1.1b911.0m706.0m905.0m567.0m284.0m535.0m375.0m556.0m1.2b

Net Income

2.6b2.3b2.9b2.7b2.4b2.6b2.1b1.3b3.0b2.0b3.6b7.4b

Pfizer Balance Sheet

Annual

usdY, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.2b10.1b2.2b3.3b3.6b

Inventories

6.2b5.7b

Current Assets

56.2b57.7b43.8b38.9b

PP&E

12.4b11.8b

Goodwill

42.5b42.1b48.2b54.4b

Total Assets

172.1b169.3b167.5b171.6b

Accounts Payable

3.2b3.4b3.6b4.5b

Dividends Payable

1.7b1.7b1.9b1.9b

Short-term debt

Current Liabilities

23.4b21.6b29.4b31.1b

Long-term debt

30.5b31.5b28.8b

Total Debt

30.5b31.5b28.8b

Common Stock

461.0m

Preferred Stock

24.0m

Additional Paid-in Capital

77.3b79.0b81.0b82.7b

Retained Earnings

69.7b72.2b72.0b71.8b

Total Equity

76.6b71.6b

Debt to Equity Ratio

0.4 x0.4 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x

Financial Leverage

2.2 x2.4 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q2, 2017Q1, 2019Q2, 2019

Cash

2.1b2.9b3.4b2.4b3.6b3.7b3.1b2.3b2.7b

Inventories

6.5b6.1b6.2b6.4b5.8b5.8b7.6b7.6b8.1b8.1b

Current Assets

59.5b57.8b58.3b57.0b49.4b51.7b45.0b38.5b41.3b43.8b35.9b36.4b34.8b37.3b

PP&E

12.4b12.3b12.2b12.0b11.5b11.4b13.7b

Goodwill

42.4b42.5b42.7b42.7b41.9b41.6b47.2b56.3b48.6b50.6b54.7b55.0b56.4b55.8b

Total Assets

176.0b172.0b173.0b171.0b161.0b161.0b171.0b178.0b163.0b171.0b169.0b169.0b164.6b165.0b

Accounts Payable

2.3b2.5b3.0b3.0b2.7b2.9b3.3b3.5b3.1b3.3b3.4b3.4b3.9b4.2b

Dividends Payable

1.0m1.0m1.7b1.7b1.7b1.8b1.8b1.9b2.0b

Current Liabilities

20.4b24.8b21.9b19.9b20.2b24.1b27.8b34.8b28.7b32.1b24.9b27.2b27.4b32.2b

Long-term debt

31.8b27.6b32.3b31.7b29.4b26.7b29.1b30.4b27.8b30.5b31.8b28.9b

Total Debt

31.8b27.6b32.3b31.7b29.4b26.7b29.1b30.4b27.8b30.5b31.8b28.9b

Total Liabilities

97.2b93.7b95.7b93.1b93.1b93.7b104.0b115.0b99.6b108.0b110.0b110.0b94.1b94.9b

Common Stock

452.0m454.0m454.0m455.0m458.0m458.0m459.0m461.0m460.0m461.0m463.0m463.0m465.0m465.0m

Preferred Stock

35.0m32.0m31.0m30.0m28.0m28.0m27.0m25.0m26.0m25.0m23.0m23.0m21.0m20.0m

Additional Paid-in Capital

76.8b77.8b78.2b78.5b80.0b80.4b80.8b82.5b81.4b82.1b83.1b83.4b84.6b84.9b

Retained Earnings

70.4b72.0b71.6b74.3b74.5b73.6b74.0b72.8b75.0b73.4b74.8b74.1b90.0b89.9b

Total Equity

78.4b78.1b77.0b78.3b67.6b67.2b67.1b63.6b63.3b63.1b58.7b58.7b70.5b70.1b

Financial Leverage

2.2 x2.2 x2.2 x2.2 x2.4 x2.4 x2.5 x2.8 x2.6 x2.7 x2.9 x2.9 x2.3 x2.4 x

Pfizer Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

22.1b9.2b

Accounts Receivable

940.0m148.0m21.0m(134.0m)

Inventories

(538.0m)175.0m(199.0m)365.0m

Accounts Payable

382.0m297.0m254.0m871.0m

Cash From Operating Activities

17.8b16.9b14.5b15.9b

Purchases of PP&E

(1.2b)(1.2b)(1.4b)(1.8b)

Cash From Investing Activities

(10.6b)(5.7b)(3.0b)(7.8b)

Short-term Borrowings

(1.2b)(8.2b)

Long-term Borrowings

(4.1b)(2.1b)(3.0b)(7.7b)

Dividends Paid

(6.6b)(6.6b)(6.9b)(7.3b)

Cash From Financing Activities

(15.0b)(10.0b)(10.2b)(8.9b)

Interest Paid

1.7b1.6b1.3b1.5b

Income Taxes Paid

2.9b2.1b2.4b2.5b

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2017Q1, 2019Q2, 2019

Net Income

2.6b2.3b2.9b2.7b2.4b3.6b7.4b

Depreciation and Amortization

3.1b1.6b3.1b

Cash From Operating Activities

4.8b2.0b5.8b

Purchases of PP&E

(806.0m)(386.0m)(810.0m)

Cash From Investing Activities

3.0b9.7b8.2b

Long-term Borrowings

(4.5b)(355.0m)(3.1b)

Dividends Paid

(3.9b)(2.0b)(4.0b)

Cash From Financing Activities

(7.9b)(10.7b)(12.6b)

Interest Paid

881.0m259.0m724.0m

Income Taxes Paid

1.1b257.0m1.2b

Pfizer Ratios

USDY, 2018

EV/CFO

47.9 x

Financial Leverage

2.4 x
Report incorrect company information

Pfizer Operating Metrics

Pfizer's Properties was reported to be 501 in FY, 2017.
FY, 2014FY, 2015FY, 2016FY, 2017

Active Clinical Studies

448 338

Phase III Trials Products

22 30 34 29

Discovery Projects

91 90 96 87

Countries

125 125

Manufacturing Sites

55 64 63 58

Properties

513 595 567 501

Total Units Delivered

74 b

Vaccines Delivered

135 m
Report incorrect company information